NCT02472834View on ClinicalTrials.gov

Trial of Carbamylation in Renal Disease-Modulation With Amino Acid Therapy

NACompletedINTERVENTIONAL
Enrollment

54

Participants

Timeline

Start Date

February 29, 2016

Primary Completion Date

December 31, 2020

Study Completion Date

December 31, 2020

Conditions
End Stage Renal Failure on Dialysis
Interventions
DIETARY_SUPPLEMENT

Amino acid supplementation NephrAmine®

Dialysis patients will be randomized to receive either 250 mL of NephrAmine® (5.4% amino acids for injection; B. Braun Medical, Inc) containing \~14 grams of essential amino acids during each dialysis session (3 times weekly for 8 weeks) or no treatment (standard-of-care)

Trial Locations (2)

02114

Massachusetts General Hospital, Boston

02201

Fresenius Medical Centers (local affilliates), Boston

All Listed Sponsors
collaborator

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

NIH

lead

Massachusetts General Hospital

OTHER

NCT02472834 - Trial of Carbamylation in Renal Disease-Modulation With Amino Acid Therapy | Biotech Hunter | Biotech Hunter